RxDoctor Payments DataLook up a doctor →

George Konis, MD

Family Medicine · Little Rock, ARNPI 1902884372

Payments from drug & device makers

$26,619,309in general payments, 2019–2025

Across 2,330 payments — averaging $11,425 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Research & Development, LLC$5.8M
  • Vertex$4.8M
  • Sumitomo Pharma America, Inc.$4.7M
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2.7M
  • Tris Pharma Inc$2.5M
  • Sunovion Pharmaceuticals Inc.$1.5M
  • plus $4.6M from 27 others
$972in research payments, 2019–2025

Across 6 payments — averaging $161.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$972

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Janssen Research & Development, LLC115$5,770,272
Vertex8$4,807,186
Sumitomo Pharma America, Inc.355$4,676,097
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)623$2,704,921
Tris Pharma Inc33$2,536,287
Sunovion Pharmaceuticals Inc.703$1,477,946
Regeneron17$1,091,906
AbbVie(2 entities)180$736,761
Vanda Pharmaceuticals Inc.11$669,273
Teva Pharmaceuticals USA, Inc.40$352,216
Heron Therapeutics, Inc.10$333,450
Hoffmann-la Roche Limited30$321,721
Merck21$292,001
Boehringer Ingelheim20$241,233
E.r. Squibb & Sons, L.L.C.10$168,296
Otsuka Pharmaceutical Development & Commercialization, Inc.11$162,761
Corcept Therapeutics18$92,263
Alkermes, Inc.53$35,265
Avanir Pharmaceuticals, Inc.11$35,143
GW Research Limited9$21,083
Indivior Inc.9$17,781
Biohaven Pharmaceuticals, Inc.2$13,476
Sage Therapeutics, LLC6$12,315
Supernus Pharmaceuticals, Inc.3$10,914
Acadia Pharmaceuticals Inc1$7,500
GRT US Holding, Inc.4$7,335
Dr.reddy's Laboratories,inc.1$6,900
Boehringer Ingelheim Pharma GmbH & Co.kg2$6,774
Boehringer Ingelheim RCV GmbH & Co KG14$4,955
Bioxcel Therapeutics, Inc.1$2,663
Jazz Pharmaceuticals Inc.2$1,515
Pfizer3$1,054
Novo Nordisk AS4$46

How this compares

$26,619,309 in reported general payments places this provider in the 95th percentile of 1,347 family medicine providers in Arkansas.

See all family medicine providers in Arkansas →

Medicare billing

Part B allowed, 2024
$7,012
Medicare patients
58
Services billed
114

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other family medicine in Little Rock

See the full list for Arkansas →

Where these figures come from

Is this you, or does something look wrong? →